Efsubaglutide Alfa in Chinese Adolescents With Obesity

Phase 1, randomised, double-blind trial of efsubaglutide alfa in obesity (4 arms), sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest at 18 weeks and Pharmacokinetic characteristics at steady state following multiple doses at 18 weeks. Started Jul 2026; status: recruiting.